Samuel S Leslie

US Patent:

6358678, Mar 19, 2002

Filed:

Feb 11, 1998

Appl. No.:

09/022341

Inventors:

Irina B. Bakaltcheva - Springfield VA
Alan S. Rudolph - Potomas MD
Barry J. Spargo - Baltimore MD
Samuel B. Leslie - Alexandria VA
Thomas R. Groel - Manassas VA

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

A01N 102

US Classification:

435 2, 435374

Abstract:

One aspect of the present invention is a method for storing tissues and cells (typically erythrocytes) having the step of (1) stabilizing the cells with a reversible stabilizing agent. This method typically will have the additional steps of (2) loading the cells with a cryoprotectant, and typically (3) storing the cells in liquid, frozen, or dry state. This method will also typically have the additional step of (4) prior to use, reversing the stabilization reaction. Preferably, the erythrocytes are pre-treated with CO to complex the hemoglobin with CO. It is anticipated that a practical method according to the invention will include reoxygenation of the erythrocytes, and also washing out reagents prior to in vivo use. Another aspect of the present invention is an erythrocyte that has had its shape stabilized by the reversible crosslinking of proteins in the erythrocyte, such as the structural proteins of the cytoskeleton. Another aspect of the invention is a population of such reversibly crosslinked erythrocytes.

US Patent:

6436705, Aug 20, 2002

Filed:

Jan 16, 2002

Appl. No.:

10/046297

Inventors:

Irina B. Bakaltcheva - Springfield VA
Alan S. Rudolph - Potomas MD
Barry J. Spargo - Baltimore MD
Samuel B. Leslie - Alexandria VA
Thomas R. Groel - Manassas VA

Assignee:

The United States of America as represented by the Secretary of the Navy - Washington DC

International Classification:

C12N 508

US Classification:

435372, 435366

Abstract:

One aspect of the present invention is a method for storing tissues and cells (typically erythrocytes) having the step of (1) stabilizing the cells with a reversible stabilizing agent. This method typically will have the additional steps of (2) loading the cells with a cryoprotectant, and typically (3) storing the cells in liquid, frozen, or dry state. This method will also typically have the additional step of (4) prior to use, reversing the stabilization reaction. Preferably, the erythrocytes are pre-treated with CO to complex the hemoglobin with CO. It is anticipated that a practical method according to the invention will include reoxygenation of the eryathrocytes, and also washing out reagents prior to in vivo use. Another aspect of the present invention is an erythrocyte that has had its shape stabilized by the reversible crosslinking of proteins in the erythrocyte, such as the structural proteins of the cytoskeleton. Another aspect of the invention is a population of such reversibly cross-linked erythrocytes.

US Patent:

20190355478, Nov 21, 2019

Filed:

Dec 29, 2017

Appl. No.:

16/475349

Inventors:

- McLean VA, US
Michael Jon PISHVAIAN - Potomac MD, US
Robert Joseph BENDER - Rockville MD, US
Edik Matthew BLAIS - Charlottesville VA, US
Craig HEARTWELL - Herndon VA, US
Samuel Brewster LESLIE - Burke VA, US
David Charles HALVERSON - North Bethesda MD, US
Jonathan Robert BRODY - Philadelphia PA, US

Assignee:

PERTHERA, INC. - McLean VA

International Classification:

G16H 50/70
A61B 5/00
A61N 5/10

Abstract:

A method and system for generating a therapy plan for a patient is described. The method includes providing a knowledgebase of annotated disease treatment information, a patient history database including disease types for a plurality of patients and a molecular database including molecular data associated with patients, selecting at least one of the plurality of patients for analysis, identifying a list of one or more candidate therapy plans from the knowledgebase based on at least one of the disease type and the molecular data for the at least one patient, and scoring each of the one or more candidate therapy plans by combining a molecular vector, a disease-specific vector and a patient history vector. The therapy plan with the highest score can then be selected for implementation. The system includes various hardware components for implementing the various functions as defined by the method for generating the treatment plan.